epcoritamab
abbvie,genmab
['lymsm', 'car-t', 'epcoritamab']
awesome data in r/r lbcl for epcoritamab #lymsm #eha22
61% primary refractory, 39% post car-t - orr of 63% and mos not reached 
Hematology/Oncology Fellow @MayoClinic l Alum @MedicineCU, @MedicalCollege, @UMNAlumni l malignant hem, lymphoma, clinical trials, global health l tweets=my own